

fraud, and abuse, including the elimination of bureaucratic duplication and inefficiency and the enhancement of the Government's ability to detect overpayments and fraud.

(11) To notify another Federal agency when, or to verify whether, a PIV card or HSPD-12 compliant credential is no longer valid, or to otherwise facilitate access control and visitor management at FDIC and other Federal facilities.

(12) To officials of a labor organization when relevant and necessary to their duties of exclusive representation concerning personnel policies, practices, and matters affecting working conditions.

(13) To the U.S. General Services Administration or another agency, organization, or individual for the purpose of performing audit or oversight operations in accordance with interagency or contractual agreements or as authorized by law, but only such information as is necessary and relevant to such audit or oversight function.

POLICIES AND PRACTICES FOR STORAGE OF RECORDS:

Records are stored electronically or in paper format in secure facilities. Electronic records may be stored locally on digital media, in FDIC-operated cloud environments, or in vendor cloud service offerings that are appropriately authorized and/or certified.

POLICIES AND PRACTICES FOR RETRIEVAL OF RECORDS:

Records are indexed and retrieved by name, SSN, date of birth, driver's license number, passport number, PIV card serial number, mailing address and/or email address.

POLICIES AND PRACTICES FOR RETENTION AND DISPOSAL OF RECORDS:

Records relating to FDIC employees, contractors or other individuals who applied for, been issued, and/or used a PIV card or HSPD-12 compliant credentials are maintained for six (6) years after separation from the FDIC and then dispositioned in accordance with approved records retention schedules. PIV cards are destroyed or deactivated after expiration, confiscation, or return. Visitor access records are maintained for five (5) years after the requested access date and then dispositioned in accordance with approved records retention schedules. Visitor passes are destroyed or deactivated after expiration, confiscation, or return.

ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SAFEGUARDS:

Records are protected from unauthorized access and improper use through administrative, technical, and

physical security measures. Administrative safeguards include written guidelines on handling personal information including agency-wide procedures for safeguarding personally identifiable information. In addition, all FDIC staff are required to take annual privacy and security training. Technical security measures within FDIC include restrictions on computer access to authorized individuals who have a legitimate need to know the information; multi-factor authentication for remote access and access to many FDIC systems; strong passwords when multi-factor authentication is not available; use of encryption for certain data types and transfers; firewalls and intrusion detection applications; and regular review of security procedures and best practices to enhance security. Physical safeguards include restrictions on building access to authorized individuals, security guard service, and maintenance of records in lockable offices and filing cabinets.

RECORD ACCESS PROCEDURES:

Individuals requesting access to records about them in this system of records should submit their request online through the FDIC FOIA Service Center at fdic.gov/foia. Alternatively, individuals can send a request in writing to the FDIC FOIA & Privacy Act Group, 550 17th Street NW, Washington, DC 20429, or email efoia@fdic.gov. Individuals will be required to provide a detailed description of the records they seek including time period when the records were created and other supporting information where possible. Individuals will be required to provide proof of identity in accordance with FDIC regulations at 12 CFR part 310.

CONTESTING RECORD PROCEDURES:

Individuals contesting the content of or requesting an amendment to their records in this system of records should submit their request online through the FDIC FOIA Service Center at fdic.gov/foia. Alternatively, individuals can send a request in writing to the FDIC FOIA & Privacy Act Group, 550 17th Street NW, Washington, DC 20429, or email efoia@fdic.gov. The request should contain the individual's reason for requesting the amendment and a description of the record (including the name of the appropriate designated system and category thereof) sufficient to enable the FDIC to identify the particular record or portion thereof with respect to which amendment is sought. Requests must specify which information is being contested, the reasons for contesting it, and the

proposed amendment to such information in accordance with FDIC regulations at 12 CFR part 310. Individuals will be required to provide proof of identity in accordance with FDIC regulations at 12 CFR part 310.

NOTIFICATION PROCEDURES:

Individuals seeking to know whether this system contains information about them should submit their request online through the FDIC FOIA Service Center at fdic.gov/foia. Alternatively, individuals can send a request in writing to the FDIC FOIA & Privacy Act Group, 550 17th Street NW, Washington, DC 20429, or email efoia@fdic.gov. Individuals will be required to provide proof of identity in accordance with FDIC regulations at 12 CFR part 310.

EXEMPTIONS PROMULGATED FOR THE SYSTEM:

None.

HISTORY:

80 FR 66982 (Oct. 30, 2015); 84 FR 35184 (Jul. 22, 2019); 90 FR 51316 (Nov. 17, 2025).

Federal Deposit Insurance Corporation.

Dated at Washington, DC, on February 18, 2026.

Jennifer M. Jones,
Deputy Executive Secretary.

[FR Doc. 2026-03432 Filed 2-19-26; 8:45 am]

BILLING CODE 6714-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2026-N-1224]

Masuu Global Solutions LLC, U.S. Agent for Extrovis AG, et al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 11 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

DATES: Approval is withdrawn as of March 23, 2026.

FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New

Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993–0002, 301–796–3471, Martha.Nguyen@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The applicants listed in table 1 have

informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests,

waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

TABLE 1—ANDAS FOR WHICH APPROVAL IS WITHDRAWN

Application No.	Drug	Applicant
ANDA 065366	Azithromycin, tablet, Equivalent to (EQ) 500 milligram (mg) base.	Masuu Global Solutions LLC, U.S. Agent for Extrovix AG, 2255 Glades Rd., Suite 324A, Boca Raton, FL 33431.
ANDA 078022	Propranolol hydrochloride (HCl), extended-release capsule, 60 mg, 80 mg, 120 mg, and 160 mg.	Do.
ANDA 090665	Lidocaine HCl, injectable, 2%	Do.
ANDA 201530	Methotrexate sodium preservative free, injectable, EQ 1 gram (gm) base/40 milliliters (mL) (EQ 25 mg base/mL).	Do.
ANDA 201689	Ifosfamide, injectable, 1 gm/20 mL (50 mg/mL) and 3 gm/60 mL (50 mg/mL).	Do.
ANDA 203063	Clindamycin palmitate HCl, for oral solution, EQ 75 mg base/5 mL.	Do.
ANDA 203122	Fluorouracil, cream, 0.5%	Do.
ANDA 203586	Lamivudine, tablet, 150 mg	Breckenridge Pharmaceutical, Inc., 200 Connell Dr., Suite 4200, Berkeley Heights, NJ 07922.
ANDA 204430	Riluzole, tablet, 50 mg	Cardinal Health Regulatory Sciences, U.S. Agent for Daito Pharmaceutical Co., Ltd., 7400 W 110th St., Suite 150, Overland Park, KS 66210.
ANDA 208643	Paliperidone, extended-release tablet, 1.5 mg, 3 mg, 6 mg, and 9 mg.	Lupin Pharmaceuticals, Inc., U.S. Agent for Lupin Limited, 400 Campus Dr., Somerset, NJ 08873.
ANDA 208817	Oxycodone HCl, solution, 5 mg/5 mL	Hikma Pharmaceuticals USA Inc., 1809 Wilson Rd., Columbus, OH 43228.

Therefore, approval of the applications listed in table 1, and all amendments and supplements thereto, are hereby withdrawn as of March 23, 2026. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from table 1. Introduction or delivery for introduction into interstate commerce of products listed in table 1 without an approved new drug application or ANDA violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)). Drug products that are listed in table 1 that are in inventory on March 23, 2026 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–03411 Filed 2–19–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2025–D–2837]

Questions and Answers About Requirements for Additional Traceability Records for Certain Foods; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA, we, or the Agency) is announcing the availability of a draft guidance for industry entitled “Questions and Answers About Requirements for Additional Traceability Records for Certain Foods.” The draft guidance answers questions about the final rule entitled “Requirements for Additional Traceability Records for Certain Foods,” which established additional recordkeeping requirements for persons who manufacture, process, pack, or hold foods the Agency has designated for inclusion on the Food Traceability List. The draft guidance is intended to answer questions to facilitate industry’s understanding of the final rule.

DATES: Submit either electronic or written comments on the draft guidance by May 21, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.
- If you want to submit a comment with confidential information that you